Editorial Board

Executive Editorial Board

GaBI Journal’s Executive Editorial Board comprises the Editor-in-Chief, Deputy Editors-in-Chief, Associate Editors, and Publisher.


Dr Robin Thorpe, PhD, FRCPath, Former Head of Biotherapeutics Group, National Institute for Biological Standards and Control, UK

Deputy Editor-in-Chief

Dr Robert Janknegt, PharmD, PhD, Director of Pharmacy, Orbis Medical Centre; Advisory Pharmacist, CZ Insurance Company, The Netherlands

Emeritus Editor-in-Chief

Professor Philip D Walson, MD, Board Certified in Paediatrics, Clinical Pharmacology and Medical Toxicology, USA. Visiting Professor, Institute for Clinical Chemistry, University Medical Center at Georg-August-University Medical School, Göttingen, Germany

Associate Editors

Professor Huub Schellekens, MD, Member of MEB, Professor of Medical Biotechnology, Utrecht University, The Netherlands
Professor Steven Simoens, PhD, Professor of Pharmacoeconomics, University of Leuven, Belgium


Ms Lasia Tang, Belgium

Expert Editorial Board with Associate Editors portfolios for:

  1. Bioequivalence methodology (traditional and biopharmaceutical)
  2. Biopharmaceutical production/manufacturing methodology
  3. Regulatory issues around generics and biopharmaceuticals, including national medicines boards’ perspective
  4. Clinical trials
  5. Stability studies
  6. General drug development
  7. Healthcare policies, medicines policies, and health economics
  8. Special patient populations, such as children, elderly, obese
  9. Drug safety and risk management

Source URL: https://gabi-journal.net/gabi-journal/about-gabi-journal/editorial-board

Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048